Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203

Journal of Clinical Oncology

Volumn 28, Issue 18, 2010, Pages 2947-2951

  Sun, Weijing ^a   Powell, Mark ^a   O'Dwyer, Peter J ^a   Catalano, Paul ^a   Ansari, Rafat H ^a   Benson III, Al B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; TAXOID;

ADULT; AGED; ANOREXIA; ARTICLE; BLEEDING; CLINICAL ARTICLE; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOTENSION; INFECTION; LEUKOPENIA; LOWER ESOPHAGUS SPHINCTER; LOWER ESOPHAGUS SPHINCTER ADENOCARCINOMA; LYMPHOCYTOPENIA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECTUM PERFORATION; STOMACH ADENOCARCINOMA; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; CLINICAL TRIAL; DRUG EFFECT; MIDDLE AGED; PATHOLOGY; STOMACH TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CISPLATIN; ESOPHAGOGASTRIC JUNCTION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PYRIDINES; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 77954574658     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.7988     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. CA Cancer J Clin 59:225-249, 2009
2. Waters JS, Norman A, Cunningham D, et al: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 80:269-272, 1999 (Pubitemid 29210117)
3. Cunningham D, Starling N, Rao S, et al: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36-46, 2008
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24:4991-4997, 2006 (Pubitemid 46631401)
5. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002 (Pubitemid 34716871)
6. Ferrara N: VEGF and the quest for tumor angiogenesis factors. Nat Rev Cancer 2:795-803, 2002
7. Bergers G, Song S, Meyer-Morse N, et al: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295, 2003 (Pubitemid 36554699)
8. Apperley JF, Gardembas M, Melo JV, et al: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347:481-487, 2002 (Pubitemid 34879335)
9. Wilhelm SM, Adnane L, Newell P, et al: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140, 2008
10. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109, 2004 (Pubitemid 39331023)
11. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
12. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
13. Flaherty KT, Schiller J, Schuchter LM, et al: A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 14:4836-4842, 2008
14. Mross K, Steinbild S, Baas F, et al: Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 43:55-63, 2007 (Pubitemid 46054474)
15. Gridelli C, Rossi A, Mongillo F, et al: A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: Treatment rationale and protocol dynamics. Clin Lung Cancer 8:396-398, 2007 (Pubitemid 46918286)
16. Roth AD, Fazio N, Stupp R, et al: Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: A randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 25:3217-3223, 2007 (Pubitemid 47325604)
17. Siewert JR, Stein HJ, et al: Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 85:1457-1459, 1998 (Pubitemid 28502569)
18. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000 (Pubitemid 30099779)
19. Kang YK, Kang WK, Shin DB, et al: Capecitabine/ cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: A randomised phase III noninferiority trial. Ann Oncol 20:666-673, 2009
20. Jhawer M, Tse A, Ilson D, et al: Phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma. Presented at Am Soc Clin Oncol GI Cancers Symposium, San Francisco, CA, January 15-17, 2009 (abstr 10)
21. Blumenschein GR Jr, Gatzemeier U, Fossella F, et al: Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 27:4274-4280, 2009
22. Escudier B, Szczylik C, Hutson TE, et al: Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 27:1280-1289, 2009